Ophthalmology. Retina · 2026
Associations between Systemic Tyrosine Kinase Inhibitors and Development of Age-Related Macular Degeneration in Patients with Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Shirley, Jeong Hejin, Reed Hayden A, Abbass Nadia J, Kaelber David C, Talcott Katherine E, Singh Rishi P
Аннотация
PURPOSE: To evaluate the association between systemic tyrosine kinase inhibitor (TKI) therapy and the risk of age-related macular degeneration (AMD) onset, and whether this relationship varies by anti-VEGF activity of TKIs.
DESIGN: Retrospective cohort study using a large deidentified electronic health records research platform.
PARTICIPANTS: Patients ≥50 years old with cancer encounter diagnoses were divided into groups with (treatment) and without (control) systemic TKI prescription codes and followed for incident AMD diagnosis.
METHODS: Landmarked time-to-event analyses were performed at 1, 3, and 5 years postcancer diagnosis. Treatment and control groups were propensity score matched, followed from the landmark date until incident International Classification of Diseases 10 (ICD-10) AMD encounter diagnosis, death, or last recorded clinical encounter and compared using hazard ratios (HRs) for incident AMD. A 3-arm subanalysis was also performed by stratifying TKIs by anti-VEGF activity, comparing the TKI-with-anti-VEGF and TKI-without-anti-VEGF subgroups to the control group and to each other.
MAIN OUTCOME MEASURES: Hazard ratios for an incident ICD-10 AMD encounter diagnosis code after the landmark date. Significance was defined as 95% confidence interval (CI) <0.9 and >1.1.
RESULTS: Across landmark analyses, TKI prescriptions were not consistently associated with the hazard of receiving a new ICD-10 AMD encounter diagnosis code compared with matched controls: 1 year (HR = 0.97; 95% CI = 0.85, 1.12), 3 years (HR = 0.90; 95% CI = 0.78, 1.05), and 5 years (HR = 0.81; 95% CI = 0.69, 0.96). In the subanalysis, the TKI-with-anti-VEGF subgroup showed significant reduction only at the 5-year landmark (HR = 0.60; 95% CI = 0.40, 0.89). The TKI-without-anti-VEGF subgroup demonstrated no significant association between systemic TKI exposure and the hazard of receiving a new ICD-10 AMD encounter diagnosis code at any time point: 1 year (HR = 0.98; 95% CI = 0.84, 1.15), 3 years (HR = 0.97; 95% CI = 0.82, 1.15), and 5 years (HR = 0.87; 95% CI = 0.73, 1.05). In contrast, across analyses, TKI prescriptions were consistently associated with increased hazards of mortality and fewer ophthalmology encounters.
CONCLUSIONS: This explorative study found that TKI prescriptions are not associated with incident AMD diagnosis. These findings do not support a population-level protective effect of systemic TKIs on AMD risk.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
DESIGN: Retrospective cohort study using a large deidentified electronic health records research platform.
PARTICIPANTS: Patients ≥50 years old with cancer encounter diagnoses were divided into groups with (treatment) and without (control) systemic TKI prescription codes and followed for incident AMD diagnosis.
METHODS: Landmarked time-to-event analyses were performed at 1, 3, and 5 years postcancer diagnosis. Treatment and control groups were propensity score matched, followed from the landmark date until incident International Classification of Diseases 10 (ICD-10) AMD encounter diagnosis, death, or last recorded clinical encounter and compared using hazard ratios (HRs) for incident AMD. A 3-arm subanalysis was also performed by stratifying TKIs by anti-VEGF activity, comparing the TKI-with-anti-VEGF and TKI-without-anti-VEGF subgroups to the control group and to each other.
MAIN OUTCOME MEASURES: Hazard ratios for an incident ICD-10 AMD encounter diagnosis code after the landmark date. Significance was defined as 95% confidence interval (CI) <0.9 and >1.1.
RESULTS: Across landmark analyses, TKI prescriptions were not consistently associated with the hazard of receiving a new ICD-10 AMD encounter diagnosis code compared with matched controls: 1 year (HR = 0.97; 95% CI = 0.85, 1.12), 3 years (HR = 0.90; 95% CI = 0.78, 1.05), and 5 years (HR = 0.81; 95% CI = 0.69, 0.96). In the subanalysis, the TKI-with-anti-VEGF subgroup showed significant reduction only at the 5-year landmark (HR = 0.60; 95% CI = 0.40, 0.89). The TKI-without-anti-VEGF subgroup demonstrated no significant association between systemic TKI exposure and the hazard of receiving a new ICD-10 AMD encounter diagnosis code at any time point: 1 year (HR = 0.98; 95% CI = 0.84, 1.15), 3 years (HR = 0.97; 95% CI = 0.82, 1.15), and 5 years (HR = 0.87; 95% CI = 0.73, 1.05). In contrast, across analyses, TKI prescriptions were consistently associated with increased hazards of mortality and fewer ophthalmology encounters.
CONCLUSIONS: This explorative study found that TKI prescriptions are not associated with incident AMD diagnosis. These findings do not support a population-level protective effect of systemic TKIs on AMD risk.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.